Loading…

Beta Bionics, Inc.BBNXCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of the iLet Bionic Pancreas, an automated insulin-delivery system for people with type 1 diabetes.

≈ A newer, algorithm-driven rival to Insulet's Omnipod and Tandem's t:slimMomentum neutral 49
Mkt cap
$779M
US dollars, full cap
Free float
86%
of shares outstanding
$/day
$20.0M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-63.7 pp
WACC 20.0%
Hurdle
n/a
no reverse DCF
Next earnings
132 days
30 Mar 2027
Close · USD$14.33
1D-2.6%
1W-19.5%
1M-19.2%
3M-26.4%
6M+41.7%
YTD-53.0%
1Y-47.2%
ATR %10.5%
Beta1.60
52w lowhigh56.2% off high

What Beta Bionics does

Maker of the iLet Bionic Pancreas, an automated insulin-delivery system for people with type 1 diabetes.

Sells the iLet device and then earns again and again from the disposable infusion sets and insulin cartridges patients must replace, billed largely through insurance. Distribution runs through pharmacies and medical-supply distributors, which makes insurer coverage decisions as important as sales calls.

In one line: A newer, algorithm-driven rival to Insulet's Omnipod and Tandem's t:slim.

Products and services

  • iLet Bionic Pancreas system
  • Insulin dosing algorithm/software

Customers

  • Endocrinologists
  • Type 1 diabetes patients

Where it sits in the supply chain

  • Medical devices
  • Diabetes management technology
  • Automated insulin delivery (AID) system

What could go right

  • Automated insulin delivery adoption growth
  • Simplified-dosing appeal to patients/caregivers

What could go wrong

  • Intense competition from established insulin-pump makers
  • Reimbursement/insurance coverage dependency

Moat: narrow (IP / patents, process know-how). Proprietary dosing algorithm requires only body weight (no carb counting), differentiating from rival AID systems.

Headquarters: Irvine, California · Founded: 2013 · Employees: 423

Named competitors

Beta Bionics at a glance

Size Beta Bionics (BBNX) is a United States Health Care company (Medical Specialties) with a market value of $779M, the 2387th largest of 3,085 United States companies the cockpit tracks. Shares closed at $14.33 on 18 Nov 2026.

Performance Over six months the shares gained 41.7%, against -17.5% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue grew 43.7% over the last twelve months (peer median +10.2%); the operating margin is -72.8% (peer median 12.8%).

Valuation It trades at 4.3× enterprise value to sales against a peer median of 3.1× (7th most expensive of 21).

Capital Return on invested capital runs 63.7 points below its cost of capital (20.0% WACC).

Backlog Backlog (remaining performance obligations) was $2.00M at 30 Sep 2026, up 54% on a year earlier — 0.0 years of trailing revenue. Backlog detail →

Short interest Short interest is 9.2% of the free float (30 Oct 2026).

Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026BBNX 135Peer median 84
Six months, rebased to 100: Beta Bionics against the median of its 20 peers (local-currency closes).

Beta Bionics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$127M$100M$65.1M$12.0M$179,000
Revenue growth—+54%+443%+6,601%—
Gross profit$74.6M$55.5M$35.9M$6.31M-$1.91M
EBITDA-$88.6M-$68.8M-$43.0M-$33.8M-$63.8M
Net income-$83.1M-$73.2M-$54.8M-$44.1M-$64.8M
Free cash flow-$66.0M-$56.2M-$51.7M-$32.8M-$61.0M
Capital expenditure$6.59M$5.30M$3.40M$402,000$772,000
Total debt$6.10M$7.30M$7.25M$4.22M$4.13M

Quarterly statements and history in the cockpit →

Beta Bionics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%-10%0%+10%SETLMLABCTKB1302VREX2190300463688108096530AMSMCAP002950688068300453603108688805301367BBNX6-month return →1-month return →
Up and to the right = strong over both horizons. Beta Bionics is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%2×4×6×8×SETLMLABCTKB1302VREX2190300463688108096530MCAP002950688068300453603108688805INMD600855301367688179BBNXRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Beta Bionics is the large dot.

Beta Bionics competitors and peer comparison

Head to head with its named competitors (BBNX vs PODD vs TNDM vs MDT)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Beta Bionics BBNX$779M+42%+44%-73%4.3×n/a
Insulet PODD$9.71B-11%+26%18%3.2×10.6%
Tandem Diabetes Care TNDM$1.19B+13%+7%-2%1.4×n/a
Medtronic MDT$129B+30%+10%20%4.0×9.1%
Dexcom DXCM$30.8B+16%+13%24%6.0×19.6%

How Beta Bionics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Beta Bionics against its 20 peers (data as of 18 Nov 2026)
MeasureBBNXPeer medianRank in peer set
1-month return-19.2%-6.7%4th lowest of 21
6-month return+41.7%-17.5%4th highest of 21
Distance from 52-week high-56.2%-39.8%5th lowest of 21
Revenue growth (TTM)+43.7%+10.2%2nd highest of 21
Operating margin-72.8%12.8%2nd lowest of 21
EV / Sales4.3×3.1×7th most expensive of 21
ROIC minus cost of capital-63.7 pp-0.3 pplowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Beta Bionics BBNXUnited States$779M+42%+44%-73%4.3×n/an/a
Standard Engineering Technology SETL.NSIndia$783M+168%+45%14%7.7×n/an/a
Mesa Laboratories MLABUnited States$775M+33%+2%10%3.6×21.3%+13.2%
Cytek Biosciences CTKBUnited States$774M+57%+6%-21%2.6×n/an/a
LifeTech Scientific 1302.HKHong Kong$771M-30%+1%12%3.2×9.6%+15.5%
Varex Imaging VREXUnited States$771M+79%+5%8%1.2×n/an/a
Zylox-Tonbridge Medical Technology 2190.HKHong Kong$768M-16%+39%25%3.6×3.8%+105.8%
Maccura Biotechnology 300463.SZChina$756M-18%-1%-4%2.3×7.9%-10.2%
Sino Medical Sciences Technology 688108.SSChina$753M-41%+22%19%7.8×27.9%+9.9%
Seegene 096530.KSSouth Korea$808M-26%+13%13%1.2×-6.7%-15.9%
Advanced Medical Solutions AMS.LUnited Kingdom$811M+27%+6%12%3.0×20.0%+21.4%
MedCap MCAP.STSweden$811M-4%+17%15%3.6×2.7%+20.9%
Allmed Medical Products 002950.SZChina$747M-32%+14%8%1.5×n/an/a
Beijing Hotgen Biotech 688068.SSChina$815M-37%+8%-94%9.6×n/an/a
Jiang Xi Sanxin Medtec 300453.SZChina$744M-3%+12%18%2.8×-1.9%+11.8%
Shanghai Runda Medical Technology 603108.SSChina$744M-36%-12%-2%1.7×20.3%-0.2%
Ningbo Jansen Superconducting Technologies 688805.SSChina$818M-36%+36%16%6.8×35.6%+17.1%
InMode INMDUnited States$741M-8%+2%18%0.6×-10.8%+12.4%
Beijing Aerospace Changfeng 600855.SSChina$738M-44%-10%-19%4.5×n/an/a
BMC Medical 301367.SZChina$737M-17%+37%17%1.8×-1.5%+15.6%
Shanghai Aladdin Biochemical Technology 688179.SSChina$736M-37%+39%24%5.8×17.1%+24.2%

Beta Bionics backlog

Beta Bionics reported $2.00M of remaining performance obligations at 30 Sep 2026, up 54% from a year earlier and up 5% from the previous quarter. That is 0.0 years of trailing revenue already under contract. Book-to-bill last quarter: 1.00.

Questions

Who are Beta Bionics's main competitors?
Named competitors: Insulet Corporation (PODD), Tandem Diabetes Care (TNDM), Medtronic (MDT), Dexcom (DXCM). The cockpit's measured peer set (industry) also includes Standard Engineering Technology (SETL.NS), Mesa Laboratories (MLAB), Cytek Biosciences (CTKB), LifeTech Scientific (1302.HK), Varex Imaging (VREX), Zylox-Tonbridge Medical Technology (2190.HK).
Is Beta Bionics expensive compared with its peers?
On ev / sales it trades at 4.3× against a peer median of 3.1×, 7th most expensive of 21 in its peer set.
How has Beta Bionics stock performed?
Over six months to 18 Nov 2026 the shares returned +41.7% against -17.5% for the median peer; over one year -47.2%.
What is Beta Bionics's backlog?
Beta Bionics's remaining performance obligations (contracted revenue not yet recognised) were $2.00M at 30 Sep 2026, +54% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.